Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 20/20 | 0.63 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21505120 | 0.90 | EP300 (0.65) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL31149122 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22039751 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL31149092 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL23891796 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605654 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL21505395 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL23891533 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605656 | 0.88 | EP300 (0.68) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL23891531 | 0.87 | EP300 (0.62) | EP300CREBBPCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | EP300 1/4885CREBBP 20/4885CYP3A4 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.